CRISPR Therapeutics AG

SecurityCRSP / CRISPR Therapeutics AG
InstitutionAdvisor Group Holdings, Inc.
Latest Disclosed Ownership60,056 shares
Latest Disclosed Value $ 2,856,745
Advisor Group Holdings, Inc. ownership in CRSP / CRISPR Therapeutics AG

On May 15, 2026 - Advisor Group Holdings, Inc. filed a 13F-HR form disclosing ownership of 60,056 shares of CRISPR Therapeutics AG (US:CRSP) valued at $2,856,864 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 59,211 shares of CRISPR Therapeutics AG. This represents a change in shares of 1.43% during the quarter. The current value of the position is $3,127,716 USD.

Advisor Group Holdings, Inc. has a history of taking positions in derivatives of the underlying security (CRSP) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

CRSP / CRISPR Therapeutics AG Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 60,056 845 1.43 2,857 -7.99 0.0024
2026-02-17 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 59,211 3,276 5.86 3,105 -3.18 0.0045
2025-11-14 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 55,935 3,900 7.49 3,206 26.92 0.0045
2025-09-04 2025-06-30 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 52,035 8,372 19.17 2,526 70.10 0.0045
2025-08-13 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 48,479 4,816 1,991 0.0023
2025-05-12 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 43,663 -6,253 -12.53 1,486 -23.53 0.0033
2025-06-06 2024-12-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 49,916 -34,888 -41.14 1,943 -51.26 0.0044
2025-02-07 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 45,474 -39,330 2,031 0.0052
2024-11-13 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 84,804 -3,597 -4.07 3,984 -16.55 0.0090
2024-08-13 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 88,401 -2,650 -2.91 4,774 -23.05 0.0113
2024-05-10 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 91,051 582 0.64 6,205 9.55 0.0139
2024-02-12 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 90,469 -13,052 -12.61 5,663 20.54 0.0099
2023-11-13 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 103,521 18,300 21.47 4,699 -2.00 0.0069
2023-08-21 2023-06-30 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 85,221 191 0.22 4,795 24.71 0.0086
2023-08-10 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 96,249 11,219 4,784 0.0013
2023-05-12 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 85,030 16,115 23.38 3,845 37.19 0.0072
2023-02-10 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 68,915 17,866 35.00 2,802 -15.98 0.0057
2022-11-14 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 51,049 119 0.23 3,335 6.79 0.0076
2022-08-10 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 50,930 -630 -1.22 3,123 1.79 0.0069
2022-05-04 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 51,560 3,461 7.20 3,068 -16.27 0.0060
2022-02-03 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 48,099 6,116 14.57 3,664 -21.99 0.0069
2021-11-05 2021-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 41,983 7,020 20.08 4,697 -16.79 0.0098
2021-08-02 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 34,963 4,920 16.38 5,645 54.49 0.0122
2021-05-13 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 30,043 12,476 71.02 3,654 35.79 0.0088
2021-02-10 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 17,567 -4,103 -18.93 2,691 48.67 0.0072
2020-11-12 2020-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 21,670 2,271 11.71 1,810 27.02 0.0054
2020-08-14 2020-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 19,399 222 1.16 1,425 73.57 0.0048
2020-05-18 2020-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 19,177 19,177 821 0.0034
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-02-17 2025-12-31 13F CRISPR THERAPEUTICS CALL Call 0 -100.00 0 n/a n/a n/a
2025-11-14 2025-09-30 13F CRISPR THERAPEUTICS CALL Call 3 0.00 1 n/a n/a n/a
2025-09-04 2025-06-30 13F/A CRISPR THERAPEUTICS CALL Call 3 -25.00 1 n/a n/a n/a
2025-08-13 2025-06-30 13F CRISPR THERAPEUTICS CALL Call 4 0 n/a n/a n/a
2025-05-12 2025-03-31 13F CRISPR THERAPEUTICS CALL Call 4 0.00 0 n/a n/a n/a
2025-06-06 2024-12-31 13F/A CRISPR THERAPEUTICS CALL Call 4 300.00 0 n/a n/a n/a
2025-02-07 2024-12-31 13F CRISPR THERAPEUTICS CALL Call 1 1 n/a n/a n/a
2024-11-13 2024-09-30 13F CRISPR THERAPEUTICS CALL Call 1 0.00 1 -100.00 n/a n/a n/a
2024-08-13 2024-06-30 13F CRISPR THERAPEUTICS CALL Call 1 0.00 1 -50.00 n/a n/a n/a
2024-05-10 2024-03-31 13F CRISPR THERAPEUTICS CALL Call 1 0.00 3 0.00 n/a n/a n/a
2024-02-12 2023-12-31 13F CRISPR THERAPEUTICS AG CALL NAMEN AKT Call 1 0.00 2 100.00 n/a n/a n/a
2023-11-13 2023-09-30 13F CRISPR THERAPEUTICS AG CALL NAMEN AKT Call 1 0.00 1 -50.00 n/a n/a n/a
2023-08-21 2023-06-30 13F/A CRISPR THERAPEUTICS AG CALL NAMEN AKT Call 1 0.00 2 100.00 n/a n/a n/a
2023-08-10 2023-06-30 13F CRISPR THERAPEUTICS AG CALL NAMEN AKT Call 1 2 n/a n/a n/a
2023-05-12 2023-03-31 13F CRISPR THERAPEUTICS AG CALL NAMEN AKT Call 1 1 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.